• LAST PRICE
    8.9800
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-0.2222%)
  • Bid / Lots
    7.0000/ 1
  • Ask / Lots
    14.3500/ 2
  • Open / Previous Close
    8.9223 / 9.0000
  • Day Range
    Low 8.7500
    High 9.0000
  • 52 Week Range
    Low 5.5100
    High 10.1620
  • Volume
    31,536
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 9
TimeVolumeACTU
09:44 ET5008.9224
09:55 ET3258.82
09:57 ET18868.82
10:04 ET3088.92
10:08 ET1008.93
10:27 ET2008.85
01:26 ET1718.99
02:25 ET3278.97
02:56 ET6908.99
02:59 ET64539
03:06 ET2009
03:32 ET2008.99
03:50 ET1408.99
03:55 ET12829
04:00 ET1108.98
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACTU
Actuate Therapeutics Inc
175.8M
0.0x
---
United StatesVSTM
Verastem Inc
174.9M
-1.3x
---
United StatesIMMP
Immutep Ltd
269.6M
-8.4x
---
United StatesDMAC
DiaMedica Therapeutics Inc
178.7M
-8.5x
---
United StatesINZY
Inozyme Pharma Inc
172.8M
-1.8x
---
United StatesNKTX
Nkarta Inc
172.2M
-1.3x
---
As of 2024-11-22

Company Information

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Contact Information

Headquarters
1751 RIVER RUN, SUITE 400FORT WORTH, TX, United States 76107
Phone
847-986-4190
Fax
---

Executives

Chairman of the Board
Aaron Fletcher
President, Chief Executive Officer, Director
Daniel Schmitt
Chief Financial Officer
Paul Lytle
Chief Operating Officer
Andrew Mazar
Independent Director Nominee
Jason Keyes

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$175.8M
Revenue (TTM)
---
Shares Outstanding
19.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$-0.29
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.